Heptares Expands Executive Management Team with Appointment of Daniel Grau as President
Company to advance pipeline in neurological and metabolic areas, while harnessing broader discovery platform through alliances
Focused on novel GPCR-targeted medicines, Heptares has assembled a rich pipeline of first- and best-in-class therapeutic agents for serious neurological (CNS) and metabolic disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, anxiety, chronic insomnia and type II diabetes. In addition, Heptares has signed commercial partnerships with leading pharma companies such as Takeda, AstraZeneca, Shire and Novartis.
Mr. Grau is currently a member of the Product Advisory Board of Concert Pharmaceuticals, Inc. Previously he served as President and CEO of Cortria Corporation, Chief Operating Officer of CombinatoRx, Inc. (today Zalicus), and as a business consultant to Pharmacia Corporation (today Pfizer). He earned his BA from Davidson College and holds an MPhil from Yale University.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.